August 27, 2015

Breaking News

FDA approves Amgen's Repatha to treat both HeFH and HoFH

Repatha (evolocumab) has been approved "for use in addition to diet and maximally-tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or clinical atherosclerotic cardiovascular disease, such as heart attacks or strokes, who require additional lowering of LDL cholesterol."